Breaking News Instant updates and real-time market news.

SSNLF

Samsung

$0.00

(0.00%)

, BIIB

Biogen

$280.69

-0.68 (-0.24%)

19:14
05/17/18
05/17
19:14
05/17/18
19:14

Samsung BioLogics says Biogen to exercise call option by late June, Reuters says

Samsung BioLogics (SSNLF) said that its JV partner Biogen (BIIB) would exercise its call option to boosts its interest to 50% minus one share in Samsung Bioepis, Reuters reports. Biogen issued a letter to Samsung BioLogics saying it intends to use the option by June 29, the report says. Reference Link

SSNLF

Samsung

$0.00

(0.00%)

BIIB

Biogen

$280.69

-0.68 (-0.24%)

  • 18

    May

  • 21

    May

  • 30

    May

SSNLF Samsung
$0.00

(0.00%)

05/01/18
OPCO
05/01/18
NO CHANGE
OPCO
Oppenheimer lowering estimates on Apple supply chain
Oppenheimer analyst Rick Schafer is lowering estimates on his Apple (AAPL) supply chain stocks on the heels of his colleague analyst Andrew Uerkwitz's estimate cuts reflecting widespread evidence of incremental downside in iPhone units likely in Q2. Schafer believes investors expect lower iPhone units near-term, with magnitude the only question, and estimates a 5M unit shortfall versus his prior Q2 estimates. The analyst expects a rebound in China smartphone to provide a tailwind for some, but not enough to offset an above seasonal slowdown at Samsung (SSNLF) and incremental Apple softness. Nonetheless, he remains bullish on sustained RF content gains as the market moves toward 5G, and his top picks on this theme are Broadcom (AVGO)/Skyworks (SWKS).
05/04/18
OPCO
05/04/18
NO CHANGE
Target $120
OPCO
Outperform
Oppenheimer remains a buyer of Skyworks following Q2 results
Oppenheimer analyst Rick Schafer said he remains a buyer of Skyworks (SKWS) following the company's Q2 earnings. In a research note to investors, Schafer noted that while the June quarter outlook why shy of consensus expectations, it was likely better than feared given recent Apple (AAPL)-related foodchain cuts, adding that he believes weaker iPhone units were likely aggravated by a ramp down at Samsung (SSNLF) following an above-seasonal GS9 ramp in the first calendar quarter of the year. The analyst has an Outperform rating and $120 price target on shares.
05/11/18
CHLM
05/11/18
NO CHANGE
CHLM
Immersion results, guidance beat Street estimates, says Craig-Hallum
Craig-Hallum analyst Anthony Stoss reiterated a Buy rating and $17 price target on Immersion following the company's Q1 earnings report, in which the company beat Q1 consensus estimates and raised its FY18 guidance for both revenues and non-GAAP net income. Stoss noted that March cash of ~$139M implies a sizable Apple (AAPL) win, roughly in-line with the analyst's ~$90M estimate for this part of the agreement. Stoss believes that Immersion pushed for a longer term deal with Apple, with this part of the deal representing half of what he sees as a six-year agreement, with another similar payment from Apple coming for the second half of the agreement after three years. Stoss also believes that Samsung (SSNLF) and China each represent an opportunity of similar size to Apple.
05/16/18
KEYB
05/16/18
NO CHANGE
KEYB
Surveys indicate iPhone inventories beginning to trend down, says KeyBanc
KeyBanc analyst John Vinh says his carrier surveys indicate sell-through results were largely in line with lowered expectations. The analyst notes that demand for the Galaxy Samsung (SSNLF) 9 remains "very disappointing" and inventories remain bloated, as pricing and the lack of innovation appear to be culprits. These mixed results leave him slightly more constructive on owning the mobile supply chain stocks into 2H18 given the modest decline in Apple's (AAPL) iPhone inventories. Vinh's favorite mobile names are Broadcom (AVGO), Skyworks (SWKS), and Synaptics (SYNA).
BIIB Biogen
$280.69

-0.68 (-0.24%)

04/25/18
04/25/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he is increasingly comfortable with Alphabet's positioning in digital media relative to Facebook (FB), given Alphabet's private relationship with consumers and the high utility and durability of Google's core business. 2. Verizon (VZ) upgraded to Buy from Hold at SunTrust and to Buy from Neutral at UBS. 3. Disney (DIS) upgraded to Market Perform from Underperform at BMO Capital with analyst Daniel Salmon saying the risk-reward on the stock is now more balanced, while its leading portfolio remains a long-term attraction. 4. Biogen (BIIB) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney saying he believes the shares are "too cheap" and its MS business appears more stable than he had been concerned about. 5. PulteGroup (PHM) upgraded to Buy from Neutral at B. Riley FBR and to Buy from Neutral at Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
04/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Terence Flynn saying pipeline and balance sheet optionality are taking longer to materialize than expected but valuation reflects limited value to Aducanumab or Biogen's Phase 2 neuro pipeline. 2. GrubHub (GRUB) downgraded to Neutral on valuation at Roth Capital with analyst Darren Aftahi citing valuation. 3. Paccar (PCAR) downgraded to Sector Perform from Outperform at RBC Capital and to Neutral from Buy at BofA/Merrill. 4. Caterpillar (CAT) downgraded to Neutral from Outperform at Daiwa. 5. Edwards Lifesciences (EW) downgraded to Market Perform from Outperform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/18
CANT
04/26/18
NO CHANGE
Target $272
CANT
Neutral
Biogen price target lowered to $272 from $289 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner lowered his price target for Biogen to $17 and reiterates a Neutral rating on the shares following Tuesday's Q1 results. The analyst remains concerned that the company's "out-year growth prospects are too heavily leveraged to the successful development of assets for which significant de-risking may need to occur." Further, the Biogen's multiple sclerosis franchise will continue to face competition, Tanner tells investors in a research note.
05/02/18
SBSH
05/02/18
NO CHANGE
Target $290
SBSH
Neutral
Biogen price target lowered to $290 from $360 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen to $290 saying Tecfidera "is an unanswered question and a big risk to the stock." The analyst is unsure what the generic Gilenya impact will be on Tecfidera. Biogen shares may not be at a bad entry point for long-term investors, but "we don't think this is where people need to be over the next year," Karnauskas tells investors in research note. She believes the key issue for the shares is the Alzheimer's program and expects data late in 2019 or early 2020. The analyst keeps a Neutral rating on Biogen.

TODAY'S FREE FLY STORIES

15:10
08/21/18
08/21
15:10
08/21/18
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

PSTG

Pure Storage

$22.00

0.2 (0.92%)

15:04
08/21/18
08/21
15:04
08/21/18
15:04
Options
Pure Storage options imply 10.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

CASY

Casey's General Stores

$116.05

1.33 (1.16%)

15:01
08/21/18
08/21
15:01
08/21/18
15:01
Conference/Events
Casey's General Stores management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 17

    Sep

  • 06

    Nov

RIGL

Rigel Pharmaceuticals

$2.67

0.08 (3.09%)

15:00
08/21/18
08/21
15:00
08/21/18
15:00
Hot Stocks
Rigel's Rodriguez says 'work has just begun' with Tavalisse launch »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$127.21

-0.47 (-0.37%)

15:00
08/21/18
08/21
15:00
08/21/18
15:00
Options
Electronic Arts attracts a bullish option play »

Electronic Arts attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

URBN

Urban Outfitters

$47.40

-0.12 (-0.25%)

14:49
08/21/18
08/21
14:49
08/21/18
14:49
Options
Urban Outfitters options imply 12.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

SFIX

Stitch Fix

$34.77

1.92 (5.84%)

14:45
08/21/18
08/21
14:45
08/21/18
14:45
Options
Stitch Fix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 01

    Oct

ATVI

Activision Blizzard

$69.63

0.7 (1.02%)

14:40
08/21/18
08/21
14:40
08/21/18
14:40
Periodicals
Breaking Periodicals news story on Activision Blizzard »

M Science says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

NURO

NeuroMetrix

$1.26

0.04 (3.28%)

, GSK

GlaxoSmithKline

$41.57

0.25 (0.61%)

14:32
08/21/18
08/21
14:32
08/21/18
14:32
Hot Stocks
NeuroMetrix receives $3.8M milestone payment under its pact with GSK »

NeuroMetrix (NURO)…

NURO

NeuroMetrix

$1.26

0.04 (3.28%)

GSK

GlaxoSmithKline

$41.57

0.25 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

14:30
08/21/18
08/21
14:30
08/21/18
14:30
General news
Canada Retail Sales Preview »

Canada Retail Sales…

14:25
08/21/18
08/21
14:25
08/21/18
14:25
General news
Treasury Option Action: more bond positioning »

Treasury Option Action:…

MDT

Medtronic

$95.02

4.96 (5.51%)

14:20
08/21/18
08/21
14:20
08/21/18
14:20
Recommendations
Medtronic analyst commentary  »

Medtronic momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 05

    Sep

  • 12

    Sep

MS

Morgan Stanley

$48.75

0.48 (0.99%)

14:20
08/21/18
08/21
14:20
08/21/18
14:20
Options
Mega option block in Morgan Stanley »

Mega option block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/21/18
08/21
14:17
08/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$2.65

0.06 (2.32%)

14:16
08/21/18
08/21
14:16
08/21/18
14:16
Hot Stocks
Rigel CEO says impact of any Trump policy still unclear »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/21/18
08/21
14:16
08/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$339.67

11.92 (3.64%)

, AAPL

Apple

$216.73

1.25 (0.58%)

14:07
08/21/18
08/21
14:07
08/21/18
14:07
Periodicals
Netflix testing how to bypass iTunes billing in 33 countries, TechCrunch says »

Netflix (NFLX) is…

NFLX

Netflix

$339.67

11.92 (3.64%)

AAPL

Apple

$216.73

1.25 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

UAL

United Continental

$86.00

0.765 (0.90%)

14:06
08/21/18
08/21
14:06
08/21/18
14:06
Periodicals
United's Kirby sees average airfares improving, Bloomberg reports »

As U.S. rivals offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

APO

Apollo Global

$34.44

0.22 (0.64%)

, BX

Blackstone

$36.48

-0.32 (-0.87%)

14:04
08/21/18
08/21
14:04
08/21/18
14:04
Periodicals
PE firms eyeing acquisitions of local TV assets, CNBC reports »

Apollo Global (APO),…

APO

Apollo Global

$34.44

0.22 (0.64%)

BX

Blackstone

$36.48

-0.32 (-0.87%)

NXST

Nexstar

$80.25

1.05 (1.33%)

TRCO

Tribune Media

$35.98

0.91 (2.59%)

SBGI

Sinclair Broadcast

$29.30

0.55 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 06

    Sep

UAL

United Continental

$86.32

1.085 (1.27%)

14:00
08/21/18
08/21
14:00
08/21/18
14:00
Options
Heavy call activity in UAL as shares take off »

Heavy call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RIGL

Rigel Pharmaceuticals

$2.66

0.07 (2.70%)

13:52
08/21/18
08/21
13:52
08/21/18
13:52
Hot Stocks
Rigel's Rodriguez says physician response to Tavalisse 'very positive' »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCI

Johnson Controls

$39.84

1.11 (2.87%)

13:50
08/21/18
08/21
13:50
08/21/18
13:50
Options
Notable call spread in Johnson Controls as shares rally »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$287.20

1.52 (0.53%)

, SPX

S&P 500

$0.00

(0.00%)

13:46
08/21/18
08/21
13:46
08/21/18
13:46
Periodicals
Michael Cohen enters plea deal with federal prosecutors, ABC News says »

Tom Llamas, ABC…

SPY

SPDR S&P 500 ETF Trust

$287.20

1.52 (0.53%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.35

0.5 (3.15%)

13:45
08/21/18
08/21
13:45
08/21/18
13:45
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
08/21/18
08/21
13:40
08/21/18
13:40
General news
FOMC minutes preview: »

FOMC minutes preview: the…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.